Assessment of Tocilizumab in the Treatment of Cancer Cachexia

被引：27

作者：

Berti, Alvise ^{[1
]}

Boccalatte, Francesco ^{[1
]}

Sabbadini, Maria Grazia ^{[1
]}

Dagna, Lorenzo ^{[1
]}

机构：

[1] San Raffaele Univ, San Raffaele Sci Inst, Milan, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 23期

关键词：

RECEPTOR ANTIBODY; INTERLEUKIN-6; CHEMOTHERAPY;

D O I：

10.1200/JCO.2012.48.4147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：2970 / 2970

页数：1

相关论文

共 10 条

[1]

Possible Role for Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia [J].

Ando, Katsutoshi ;

Takahashi, Fumiyuki ;

Motojima, Shinji ;

Nakashima, Kei ;

Kaneko, Norihiro ;

Hoshi, Kazuei ;

Takahashi, Kazuhisa .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) :E69-E72

[2]

Interleukin 6 as a Key Regulator of Muscle Mass during Cachexia [J].

Carson, James A. ;

Baltgalvis, Kristen A. .

EXERCISE AND SPORT SCIENCES REVIEWS, 2010, 38 (04) :168-176

[3]

Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy [J].

Chang, Chin Hao ;

Hsiao, Chin Fu ;

Yeh, Yu Min ;

Chang, Gee Chen ;

Tsai, Ying Huang ;

Chen, Yuh Min ;

Huang, Ming Shyan ;

Chen, Hui Ling ;

Li, Yao Jen ;

Yang, Pan Chyr ;

Chen, Chien Jen ;

Hsiung, Chao A. ;

Su, Wu Chou .

INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (09) :1977-1985

[4]

Chumlea WC, 1995, J GERONTOL A BIOL SC, V50

[5]

European Medicines Agency, ROACTEMRA EPAR PRODU

[6]

Laviano A, 2005, NAT CLIN PRACT ONCOL, V2, P158, DOI 10.1038/ncponc0112

[7]

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients [J].

Monk, JP ;

Phillips, G ;

Waite, R ;

Kuhn, J ;

Schaaf, LJ ;

Otterson, GA ;

Guttirdge, D ;

Rhoades, C ;

Shah, M ;

Criswell, T ;

Caligiuri, MA ;

Villalona-Calero, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) :1852-1859

[8]

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease [J].

Nishimoto, Norihiro ;

Terao, Kimio ;

Mima, Toru ;

Nakahara, Hideko ;

Takagi, Nobuhiro ;

Kakehi, Takahiro .

BLOOD, 2008, 112 (10) :3959-3964

[9]

PROPERTIES OF 4 ACUTE PHASE PROTEINS - C-REACTIVE PROTEIN, SERUM AMYLOID-A PROTEIN, ALPHA-1-ACID GLYCOPROTEIN, AND FIBRINOGEN [J].

SCHULTZ, DR .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 1990, 20 (03) :129-147

[10]

Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer [J].

Tan, Benjamin H. L. ;

Birdsell, Laura A. ;

Martin, Lisa ;

Baracos, Vickie E. ;

Fearon, Kenneth C. H. .

CLINICAL CANCER RESEARCH, 2009, 15 (22) :6973-6979